AstraZeneca today announced that Duaklir® Genuair® (aclidinium bromide/formoterol fumarate 340/12 mcg) has been granted Marketing Authorisation by the European Commission (EC) to be used as a ...
MORRISVILLE, N.C.--(BUSINESS WIRE)--Circassia Pharmaceuticals Inc. (“Circassia” or “the Company”), today announced the launch of DUAKLIR® PRESSAIR® (aclidinium bromide and formoterol fumarate) for the ...
MORRISVILLE, N.C.--(BUSINESS WIRE)--Circassia Pharmaceuticals Inc. (“Circassia” or “the Company”), today announced that the US Food and Drug Administration has approved DUAKLIR® PRESSAIR® (aclidinium ...
DUAKLIR™ GENUAIR® now available in Canada for the treatment of chronic obstructive pulmonary disease
MISSISSAUGA, ON, Oct. 29, 2015 /CNW/ - AstraZeneca Canada announced today that DUAKLIR ™ GENUAIR ® (aclidinium bromide/formoterol fumarate dihydrate 400/12 μg) is now available in Canada for the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results